Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics
Source: SeekingAlpha
2025-11-06 08:50:28 ET
More on Avenue Therapeutics, Axsome Therapeutics
- Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer
- Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript
- Axsome Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation
- Axsome anticipates expanded market access for SYMBRAVO and AUVELITY while advancing late-stage pipeline
- Axsome Therapeutics GAAP EPS of -$0.94 misses by $0.07, revenue of $171M beats by $8.01M
Read the full article on Seeking Alpha
For further details see:
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics
Avenue Therapeutics Inc.
NASDAQ: ATXI
ATXI Trading
-30.71% G/L:
$0.42 Last:
1,156,557 Volume:
$0.549 Open:
ATXI Latest News
February 23, 2026 08:00:00 am
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
November 06, 2025 07:00:00 am
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
ATXI Stock Data
$609,906
2,909,772
15.99%
9
51383%
Biotechnology & Life Sciences
Healthcare
US
Bay Harbor Islands
